Knowing how a virus is spread, also from a cell biology point-of-view, is critical to curtailing its spread and devising effective treat...

As if Ebola has not showered Tekmira with enough attention, Tekmira will be front and center in the RNA Therapeutics industry in October...

Today, Tekmira disclosed that an acceptable regulatory pathway has been found with US and Canadian regulators to use its RNAi Therapeutic...

Canadian drug developer Tekmira just disclosed that the FDA verbally notified them that it would partially lift the clinical hold it had ...

(please read financial conflict at the end) We are in the midst of the largest recorded outbreak of Ebola hemorrhagic fever virus ever...

Like it or not, it is the HBV program that is driving the interest in Tekmira, at least in the near-term.  Therefore, the 15% sell-off i...

There could not have been a worse timing for the Clinical Halt imposed on Tekmira’s RNAi candidate for the treatment of Ebola viral in...

At the annual gathering of the gene therapy community today, Tekmira presented  an update on their ongoing phase I trial with TKM-Ebola, t...

A day or so following reassurances by the Guinean authorities that the Ebola virus outbreak had been contained and was under control, n...

In German, a Haertetest  is a test that challenges the performance of something under the most exacting conditions.   It is therefore ...

Viral infections have long been thought of as an attractive therapeutic area for RNAi Therapeutics.  Unfortunately, with the exception of...

On Monday, Tekmira announced that it has received the Green Light from the FDA to go ahead with clinical studies of its SNALP-enabled biode...

I was quite amused today, while driving a car on Borneo, the local radio report the headline ‘US scientists said that they are ready to star...